BrightPath Biotherapeutics Co., Ltd. (TYO:4594)

Market Cap	7.87B
Revenue (ttm)	1.13M
Net Income (ttm)	-1.15B
Shares Out	90.49M
EPS (ttm)	-14.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,103,700
Average Volume	15,824,170
Open	86.00
Previous Close	87.00
Day's Range	83.00 - 89.00
52-Week Range	32.00 - 114.00
Beta	1.17
RSI	57.94
Earnings Date	Aug 8, 2025

About TYO:4594

BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. It is developing GRN-1201, a cancer peptide vaccine candidate that is in Phase II clinical trials for the treatment of non-small cell lung cancer, as well as in Phase I clinical trials to treat melanoma. The company is also developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 42
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4594

Financial Performance

In 2024, TYO:4594's revenue was 1.13 million, an increase of 1473.61% compared to the previous year's 72,000. Losses were -1.15 billion, -1.45% less than in 2023.